Protocol Ledger

NCT07589595 · Phase II · RECRUITING

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Interventional Phase II clinical trial protocol NCT07589595 sponsored by Eli Lilly and Company in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-20 Enrollment: 350 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07589595
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07589595
Protocol FieldVerified Registry Value
NCT IdentifierNCT07589595
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment350 participants (ESTIMATED)
Registered Start Date2026-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07589595
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI